|Videos|April 17, 2022
Dr. Talley on “landmark study” of investigational oral treatment for complicated UTIs
Author(s)Urology Times staff
“If approved, tebipenem could provide a new oral treatment option for patients with cUTI who have limited or no alternative oral options," says Angela Talley, MD.
Advertisement
In this video, Angela Talley, MD, discusses next steps and the take-home message for the recent New England Journal of Medicine paper, “Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection,” for which she served as senior author. Talley is senior vice president of Clinical Development at Spero Therapeutics.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Sildenafil cream for female sexual arousal disorder available to prescribe in select states
2
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
3
FDA approves ProVee System for benign prostatic hyperplasia
4
FDA approves first-line Zenflow system for the treatment of BPH
5
